Funding for this research was provided by:
Janssen Research and Development
Received: 11 August 2021
Accepted: 25 April 2022
First Online: 10 July 2022
: The study protocols for ASPIRE I and II were reviewed by an Independent Ethics Committee (IEC) or Institutional Review Board (IRB). For both ASPIRE I and II, patients or their legally acceptable representatives provided their written consent to participate in the study after having been informed about the nature and purpose of the study, participation/termination conditions, and risks and benefits of treatment.
: All authors provide consent for publication.
: All authors are employees of Janssen and may own stock or stock options.